



Original Investigation | Geriatrics

Association of Dual Decline in Memory and Gait Speed With Risk for Dementia Among Adults Older Than 60 Years

A Multicohort Individual-Level Meta-analysis

Qu Tian, PhD, MS; Susan M. Resnick, PhD; Michelle M. Mielke, PhD; Kristine Yaffe, MD; Lenore J. Launer, PhD; Palmi V. Jonsson, MD; Giulia Grande, MD; Anna-Karin Welmer, PhD; Erika J. Laukka, PhD; Stefania Bandinelli, MD; Antonio Cherubini, MD, PhD; Caterina Rosano, MD; Stephen B. Kritchevsky, PhD; Eleanor M. Simonsick, PhD; Stephanie A. Studenski, MD; Luigi Ferrucci, MD, PhD

Abstract

IMPORTANCE Dual decline in both memory and gait speed may characterize a group of older individuals at high risk for future dementia.

OBJECTIVE To assess the risk of dementia in older persons who experience parallel declines in memory and gait speed compared with those who experience no decline or decline in either memory or gait speed only.

DESIGN, SETTING, AND PARTICIPANTS A multicohort meta-analysis was performed of 6 prospective cohort studies conducted between 1997 and 2018 in the United States and Europe. Participants were 60 years or older, had an initial gait speed of more than 0.6 m/s (ie, free of overt disability), with repeated measures of memory and gait speed before dementia diagnosis during a mean follow-up of 6.6 to 14.5 years. Within each study, participants were divided into 4 groups: memory decline only, gait speed decline only, dual decline, or no decline (hereafter referred to as *usual agers*). Gait decline was defined as a loss of 0.05 m/s or more per year; memory decline was defined as being in the cohort-specific lowest tertile of annualized change.

MAIN OUTCOMES AND MEASURES Risk of incident dementia according to group membership was examined by Cox proportional hazards regression with usual agers as the reference, adjusted for baseline age, sex, race/ethnicity, educational level, study site, and baseline gait speed and memory.

RESULTS Across the 6 studies of 8699 participants, mean age ranged between 70 and 74 years and mean gait speed ranged between 1.05 and 1.26 m/s. Incident dementia ranged from 5 to 21 per 1000 person-years. Compared with usual agers, participants with only memory decline had 2.2 to 4.6 times higher risk for developing dementia (pooled hazard ratio, 3.45 [95% CI, 2.45-4.86]). Those with only gait decline had 2.1 to 3.6 times higher risk (pooled hazard ratio, 2.24 [95% CI, 1.62-3.09]). Those with dual decline had 5.2 to 11.7 times the risk (pooled hazard ratio, 6.28 [95% CI, 4.56-8.64]).

CONCLUSIONS AND RELEVANCE In this study, dual decline of memory and gait speed was associated with increased risk of developing dementia among older individuals, which might be a potentially valuable group for preventive or therapeutic interventions. Why dual decline is associated with an elevated risk of dementia and whether these individuals progress to dementia through specific mechanisms should be investigated by future studies.

JAMA Network Open. 2020;3(2):e1921636.

Corrected on April 3, 2020. doi:10.1001/jamanetworkopen.2019.21636

Key Points

Question Is a decline in both memory and gait speed with aging associated with a higher risk of dementia than no decline or a decline in memory or gait only in older adults?

Findings In this meta-analysis of 6 studies including 8699 participants from the United States and Europe, a decline in both memory and gait was associated with 6.28 times higher risk of developing dementia than no decline.

Meaning Older adults without dementia with parallel declines in memory and gait are associated with high risk of developing dementia and may be a group to target for prevention.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Introduction

Impaired mobility, such as slow gait, is associated with an increased risk of dementia, but the effect size of this association is generally modest.¹⁻⁶ Identifying persons who experience both mobility decline and memory decline, a main symptom in the early stage of dementia, may have a greater prognostic value in assessing risk of dementia because the combination could identify a group in whom gait speed decline is at least in part caused by neurodegenerative pathologic conditions of the central nervous system rather than local musculoskeletal problems, such as sarcopenia or osteoarthritis.⁷⁻⁹ A recent study of 154 participants with mild cognitive impairment reported that those who declined in both cognition and gait speed had the highest risk of dementia.¹⁰ However, this study population was limited to a relatively small clinical sample admitted to geriatric clinics. Whether this association occurs in general aging populations initially free of dismobility and cognitive impairment is unknown. If such an association is confirmed, it may help to identify older individuals who are free of dismobility and cognitive impairment but at high risk of developing dementia. It could also motivate investigations into whether this group develops dementia through specific pathophysiological mechanisms.

A growing line of research suggests that motoric cognitive risk syndrome, a combination of cognitive decline, slow gait, and preserved activities of daily living, is associated with high risks of cognitive impairment and dementia.¹¹⁻¹⁴ However, motoric cognitive risk syndrome is typically operationalized at 1 time point. Recent evidence suggests that assessing gait speed longitudinally rather than with a 1-time assessment better distinguishes individuals who develop dementia.¹⁰

To address these knowledge gaps, we examined whether the extreme phenotype of dual decline in memory and gait with aging compared with no decline or decline in gait or memory only would be associated with an increased risk of dementia among community-dwelling older adults. We used data from 6 prospective cohort studies in the United States and Europe to create an individual-level meta-analysis. To capture early memory and gait changes with aging, we identified participants aged 60 years or older who were initially free of dismobility, cognitive impairment, and dementia; tracked changes in memory and gait speed during the dementia-free period; and then captured incident dementia. We hypothesized that those who experienced a decline in both memory and gait speed would have a higher risk of dementia than those with no decline or with a decline in gait or memory only.

Methods

Study Population

We used individual-level data from 6 prospective cohort studies: the Baltimore Longitudinal Study of Aging (BLSA)¹⁵; the Health, Aging and Body Composition Study (Health ABC)¹⁶; the Mayo Clinic Study of Aging (MCSA)¹⁷; the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-RS)¹⁸; the InCHIANTI (Invecchiare in Chianti, Aging in the Chianti Area) study¹⁹; and the Swedish National Study on Aging and Care-Kungsholmen Population Study (SNAC-K).²⁰ The years of data collection ranged between 1997 and 2018. All studies were conducted under the oversight and approval of the institutional review boards of the institutions that conducted them. All participants consented to participate after receiving a comprehensive description of the study, including possible risks. This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.

We excluded participants who, at baseline, had prevalent cognitive impairment, dementia, and dismobility (gait speed ≤ 0.6 m/s)²¹ and who had baseline Mini-Mental State Examination (MMSE) scores of less than 24²² (BLSA, MCSA, AGES-RS, InCHIANTI, and SNAC-K) or Modified Mini-Mental State Examination scores of less than 80 (Health ABC).²³ Mild cognitive impairment or cognitive impairment was diagnosed by consensus conferences following published criteria in BLSA,²⁴ MCSA,²⁵ AGES-RS,²⁶ and InCHIANTI.¹⁹ We further excluded participants who did not have repeated

measures of memory and gait speed prior to diagnoses of dementia, last follow-up, or death because, for these individuals, we could not estimate annualized changes in memory and gait speed.

Phenotypic Groups

Within each study, participants were classified into 4 phenotypic groups based on annualized changes in memory and gait speed prior to diagnoses of dementia, last follow-up, or death. Usual gait speed for a distance of 7.6 m (25 ft) in MCSA or a distance of 6 m in all other studies was used for analysis. Gait speed was harmonized to the same unit in meters per second. Specifically, in InCHIANTI, we converted a 4-m gait speed to a 6-m gait speed.²⁷ In Health ABC, we converted a 20-m gait speed assessed at years 2, 3, 5, and 8 to a 6-m gait speed.²⁸ In MCSA, gait speed was simply expressed as meters (25 ft; 7.62 m) divided by time in seconds.²⁹ Except in MCSA and SNAC-K, which conducted only 1 trial, usual gait speed was assessed in 2 trials, and the faster trial was used for analysis.

Across the 6 studies, we focused on verbal episodic memory when available, especially immediate recall, because it was among the first cognitive functions to decline among Alzheimer disease-related cognitive measures.³⁰ Specifically, memory was assessed using the California Verbal Learning Test in BLSA,³¹ the Buschke Selective Reminding Test in Health ABC,³² the Rey Verbal Learning Test in MCSA,^{17,33} the modified California Verbal Learning Test in AGES-RS,³¹ the MMSE memory subscore in InCHIANTI,³⁴ and a free recall test in SNAC-K.³⁵

Outcome

Dementia was ascertained based on the *Diagnostic and Statistical Manual of Mental Disorders* (Third Edition Revised)³⁶ in BLSA; the *Diagnostic and Statistical Manual of Mental Disorders* (Fourth Edition) (*DSM-IV*) in MCSA and SNAC-K; race-specific decline in Modified Mini-Mental State Examination scores, medication use, and hospital records in Health ABC³⁷; a 3-step consensus adjudication following *DSM-IV* criteria in AGES-RS¹⁸; and a 2-stage screening procedure following *DSM-IV* criteria in InCHIANTI.³⁸ Within each study, the end point was at diagnoses of dementia for those who developed dementia or at last follow-up or death for those who did not develop dementia. Detailed assessment and study designs are presented in eTable 1 in the [Supplement](#).

Statistical Analysis

Within each study, annual rates of change in memory and gait speed prior to diagnoses of dementia, last follow-up, or death were first computed using simple linear regression. Participants were then classified into 4 phenotypic groups, using cut points of annualized decline in gait speed equal to or greater than 0.05 m/s³⁹ and the lowest tertile of annualized decline in memory performance. Specifically, those with less than 0.05 m/s annualized decline in gait speed and in the middle and highest tertiles (ie, less decline) of annualized decline in memory were referred to as *usual agers*. Those with less than 0.05 m/s annualized decline in gait speed but in the lowest tertile of annualized decline in memory were referred to as participants with memory decline only. Those with equal to or greater than 0.05 m/s annualized decline in gait speed and in the middle and highest tertile of annualized decline in memory were referred to as participants with gait decline only. Those with equal to or greater than 0.05 m/s annualized decline in gait speed and in the lowest tertile of annualized decline in memory were referred to as participants with dual decline. In InCHIANTI, individual slopes of MMSE memory subscores were estimated using a random-effects Poisson model owing to its distribution.

We first examined whether baseline gait speed and memory differed between groups, using multiple linear regression with usual agers being the reference group, adjusting for baseline age, sex, educational level, race/ethnicity, and study site. We then examined associations of baseline gait speed and memory performance with incident dementia using Cox proportional hazards regression, accounting for demographic characteristics.

We examined associations of phenotypic groups with incident dementia using Cox proportional hazards regression, with usual agers being the reference group, adjusting for demographic characteristics and baseline gait speed and memory performance. In Health ABC, because Buschke Selective Reminding Test began at year 3, the estimated intercept at baseline by simple linear regression was used as the covariate.

The mean risk of dementia among participants with memory decline, participants with gait decline, and participants with dual decline across the 6 studies was examined using random-effects meta-analysis, following guidelines from the *Cochrane Handbook for Systematic Reviews of Interventions*.⁴⁰ The findings are presented as forest plots and reported following published guidelines.⁴¹ Heterogeneity among studies was examined using the Cochrane χ^2 test. The amount of variation across studies that was due to heterogeneity was indicated by I^2 , expressed as a percentage. We performed sensitivity analyses by excluding 2 studies in which dementia was ascertained a posteriori (Health ABC and InCHIANTI). We performed additional sensitivity analyses by adjusting for baseline multimorbidity and specific diseases important for declines in memory and gait, including hypertension, cardiovascular disease, and stroke.

To evaluate whether changes in gait speed and memory added prognostic value beyond baseline gait speed and memory, we compared 2 models using likelihood ratio tests. To examine whether the risk of dementia associated with gait decline was similar for those with and those without memory decline, we added an interaction term between slope of memory decline and slope of gait decline in Cox proportional hazards regression. A significant interaction would reject the null hypothesis that the risk of developing dementia associated with gait decline was the same for participants with and participants without memory decline.

Statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc) and R, version 3.5.0 (R Project for Statistical Computing). All *P* values were from 2-sided tests and results were deemed statistically significant at *P* < .05.

Results

All 6 studies of 8699 participants included both men and women (**Table 1**). The BLSA and Health ABC study populations were racially/ethnically diverse and included a substantial proportion of black participants. Other studies had almost all or exclusively white participants. At baseline, the mean age across studies ranged between 70 and 74 years. The mean gait speed ranged between 1.05 and 1.26 m/s. The mean follow-up time ranged between 6.6 and 14.5 years. Across the 6 studies of 8699 participants, incident dementia ranged from 5 to 21 per 1000 person-years.

Compared with usual agers, after adjustment, participants with gait decline and participants with dual decline had faster baseline gait speed in all studies except InCHIANTI. Baseline gait speed did not differ between participants with memory decline and usual agers in all studies (eTable 2 in the [Supplement](#)).

Compared with usual agers, participants with memory decline and participants with dual decline had higher baseline memory performance in all studies except InCHIANTI and BLSA. Baseline memory did not differ between participants with gait decline and usual agers except in Health ABC, in which participants with gait decline had poorer baseline memory performance (eTable 2 in the [Supplement](#)).

After adjustment, poorer baseline memory performance was associated with a higher risk of developing dementia in all studies except InCHIANTI. Slower baseline gait speed was associated with a higher risk of dementia in all studies except BLSA (**Table 2**; model 1).

Compared with usual agers, participants with dual decline and participants with memory decline had a significantly higher risk of developing dementia consistently across all studies after adjustment for demographic characteristics and baseline memory and gait speed (Table 2; model 2; eFigure in the [Supplement](#)). Specifically, participants with dual decline had 5.2 to 11.7 times higher risk of developing dementia compared with usual agers, with a pooled hazard ratio (HR) of 6.28 (95% CI,

4.56-8.64) (Figure, C).¹⁵⁻²⁰ Participants with only memory decline had 2.2 to 4.6 times higher risk, with a pooled HR of 3.45 (95% CI, 2.45-4.86) (Figure, A).¹⁵⁻²⁰ Participants with only gait decline had 2.1 to 3.6 times the risk (pooled HR, 2.24; 95% CI, 1.62-3.09) (Figure, B).¹⁵⁻²⁰ Associations of gait decline with dementia risk were significant in Health ABC, InCHIANTI, and SNAC-K but not significant in BLSA, MCSA, and AGES-RS. Meta-analyses results remained similar after excluding 2 studies in which dementia was ascertained a posteriori: compared with usual agers, participants with dual decline had a pooled HR of 5.40 (95% CI, 4.95-5.89), participants with only memory decline had a pooled HR of 3.62 (95% CI, 2.22-5.90), and participants with only gait decline had a pooled HR of 2.01 (95% CI, 1.36-2.98). Adjustment for multimorbidity and specific diseases did not substantially alter the results (eTable 3 in the Supplement).

Table 1. Baseline Sample Characteristics

Characteristic	BLSA (N = 664)	Health ABC (N = 727)	MCSA (N = 2633)	AGES-RS (N = 2563)	InCHIANTI (N = 553)	SNAC-K (N = 1559)
Study entry	2006 ^a	1997/1998	2004	2002	1998	2001-2004
Study site	Baltimore, MD	Pittsburgh, PA; Memphis, TN	Olmsted County, MN	Iceland	Greve in Chianti, Bagno a Ripoli, Italy	Stockholm, Sweden
Demographic						
Age, mean (SD) [range], y	73.3 (8.2) [60-95]	73.5 (2.7) [69-81]	74.3 (7.0) [60-91]	74.4 (4.5) [66-91]	71.8 (5.3) [65-91]	70.4 (8.9) [60-97]
Women, No. (%)	329 (50)	371 (51)	1266 (48)	1491 (58)	293 (53)	947 (61)
Black race/ethnicity, No. (%)	140 (21)	315 (43)	5 (0.2)	0	0	0
Educational level, mean (SD) [range], y	17.6 (2.7) [7-32]	13.7 (2.8) [3-18]	14.5 (2.7) [5-20]	No. (%), 783 (31) >high school	6.3 (3.4) [0-22]	No. (%), 658 (42) >high school
Body mass index, mean (SD) [range] ^b	26.8 (4.4) [17.8-45.6]	27.0 (4.5) [15.6-48.0]	28.3 (5.2) [16.9-57.8]	27.3 (4.1) [15.6-47.5]	27.4 (3.9) [18-47]	26.0 (3.7) [16-47]
Global mental status ^c						
Median (IQR) score [range]	MMSE 29 (28-30) [24-30]	3MS 94 (90-97) [80-100]	MMSE 28 (27-29) [24-30]	MMSE 28 (27-29) [24-30]	MMSE 27 (26-28) [24-30]	MMSE 29 (29-30) [25-30]
Memory performance ^c						
Mean (SD) score [range]	CVLT 51.0 (12.0) [6-80]	SRT 46.8 (11.3) [2-72]	AVLT 40.7 (9.3) [13-69]	Modified CVLT 28.6 (7.1) [0-57]	MMSE memory subscore 5 (4-6) [3-6] ^d	Word recall 7.5 (2.3) [0-16]
Gait speed, m/s ^e						
Mean (SD) speed [range]	1.16 (0.21) [0.61-1.97]	1.26 (0.24) [0.69-2.0]	1.12 (0.23) [0.64-1.91]	1.05 (0.18) [0.61-1.74]	1.19 (0.22) [0.62-2.0]	1.21 (0.29) [0.61-2.00]
Incident dementia						
No. (%)	45 (7)	130 (18)	92 (3)	254 (10)	123 (22)	165 (11)
Per 1000 person-years	8	14	5	9	21	10
No. of visits, mean (SD) [range] ^f	4.2 (1.8) [2-12]	8 (1) [3-9]	4.5 (2.1) [2-11]	2 (0) ^g	3.6 (1.1) [2-5]	3 (1) [2-5]
Follow-up time, mean (SD) [range], y	8.3 (2.8) [2.0-13.1]	12.2 (3.0) [3.9-17.1]	6.6 (2.9) [1.3-13.0]	10.7 (1.6) [4.7-13.0]	14.5 (4.4) [3-20]	10.0 (2.7) [2-14]
No. of visits per year, mean (SD) [range]	1 (0.3) [0.2-2.0]	1 (0.1) [0.5-1.5]	1 (0.3) [0.2-2.2]	0.4 (0.02) [0.2-0.8]	0.5 (0.1) [0.2-0.7]	0.3 (0.1) [0.1-1.0]
Phenotypic groups, No. (%)						
No memory or gait speed decline	375 (56)	422 (58)	1383 (53)	1519 (59)	291 (53)	674 (43)
Memory decline only	170 (26)	202 (28)	616 (23)	743 (29)	164 (30)	309 (20)
Gait decline only	67 (10)	63 (9)	373 (14)	177 (7)	61 (11)	365 (23)
Dual decline in memory and gait speed	52 (8)	40 (6)	261 (10)	124 (5)	37 (7)	211 (14)

Abbreviations: 3MS, Modified Mini-Mental State Examination; AGES-RS, Age, Gene/Environment Susceptibility-Reykjavik Study; AVLT, Auditory Verbal Learning Test; BLSA, Baltimore Longitudinal Study of Aging; CVLT, California Verbal Learning Test; Health ABC, Health, Aging and Body Composition Study; InCHIANTI, Invecchiare in Chianti, Aging in the Chianti Area; IQR, interquartile range; MCSA, Mayo Clinic Study of Aging; MMSE, Mini-Mental State Examination; SNAC-K, The Swedish National Study on Aging and Care in Kungsholmen; SRT, Buschke Selective Reminding Test.

^a The initial assessment of 6-m gait speed started in 2006, although the BLSA began in 1958. The sample in the Health ABC is from the Cognitive Vitality Substudy.

^b Calculated as weight in kilograms divided by height in meters squared.

^c A higher score indicates higher performance. The range of possible scores is 0 to 30 for the MMSE and 0 to 100 for the 3MS.

^d The MMSE memory subscore is shown as median (IQR).

^e A higher value indicate higher performance.

^f Only visits where memory function and gait speed were assessed and used to define the phenotypic classification.

^g In AGES-RS, gait and memory were assessed only twice with a mean (SD) interval of 5 (0.3) years.

Based on likelihood ratio tests performed consistently across the 6 studies, models including information on change over time yielded a lower Akaike information criterion and a significant model change compared with models including information on baseline gait speed and baseline memory only, indicating a better fit (eTable 4 in the Supplement).

In BLSA, Health ABC, and SNAC-K, the interaction between slope of memory decline and slope of gait decline was significant in Cox proportional hazards regression models associated with dementia risk (BLSA: β [SE], -1.285 [0.495]; $P = .01$; Health ABC: β [SE], -3.071 [1.137]; $P = .006$; and SNAC-K: β [SE], -7.590 [2.403]; $P = .001$). In MCSA, findings were not significant (β [SE], 0.595 [0.362]; $P = .10$). In AGES-RS and InCHIANTI, the interaction term was also not significant (AGES-RS: β [SE], 2.10 [1.51]; $P = .16$; InCHIANTI: β [SE], -0.053 [0.053]; $P = .31$ [in InCHIANTI, the slope of gait and slope of memory (by Poisson) were multiplied by 100 owing to small values]).

Discussion

Across 6 large cohort studies of aging, dual decline in both memory and gait speed during the dementia-free period was associated with high risk of developing dementia. Our findings are consistent with the recent report by Montero-Odasso and colleagues.¹⁰ Our data further contribute to the literature by confirming these findings in 6 geographically and culturally diverse aging studies, focusing on memory function, rather than global cognition, and by characterizing early phenotype when participants are free of disability, cognitive impairment, and dementia.

Poorer baseline memory was associated with a higher risk of dementia except in InCHIANTI. The lack of an association in InCHIANTI may be due to the use of the MMSE memory subscore, a poorly sensitive measure of memory. In all studies except BLSA, slower baseline gait speed was associated with a higher risk of dementia, consistent with prior findings.¹ The lack of an association in BLSA

Table 2. Associations of Phenotypic Groups With Subsequent Dementia Risk^a

Phenotype	BLSA (N = 664)		Health ABC (N = 727)		MCSA (N = 2633)		AGES-RS (N = 2563)		InCHIANTI (N = 553)		SNAC-K (N = 1559)	
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Model 1												
Baseline memory	0.951 (0.926-0.977)	<.001	0.983 (0.966-1.000)	.04	0.942 (0.917-0.969)	<.001	0.946 (0.928-0.965)	<.001	1.008 (0.836-1.215)	.93	0.923 (0.867-0.982)	.01
Baseline gait speed, m/s	1.270 (0.261-6.190)	.76	0.259 (0.104-0.643)	.004	0.228 (0.080-0.650)	.005	0.293 (0.135-0.633)	.001	0.279 (0.106-0.734)	.009	0.440 (0.236-0.818)	.009
Model 2												
No memory or gait speed decline	[Reference]	NA	[Reference]	NA	[Reference]	NA	[Reference]	NA	[Reference]	NA	[Reference]	NA
Memory decline only	4.473 (2.036-9.826)	<.001	4.323 (2.786-6.709)	<.001	4.362 (2.603-7.310)	<.001	2.619 (1.965-3.492)	<.001	2.252 (1.478-3.432)	<.001	4.633 (2.916-7.359)	<.001
Gait decline only	2.418 (0.789-7.411)	.12	2.166 (1.108-4.233)	.02	1.889 (0.915-3.902)	.08	1.558 (0.945-2.568)	.08	3.629 (1.971-6.683)	<.001	2.503 (1.564-4.006)	<.001
Dual decline in memory and gait speed	5.912 (2.252-15.524)	<.001	11.722 (6.346-21.651)	<.001	5.810 (3.040-11.104)	<.001	5.206 (3.484-7.781)	<.001	6.993 (3.654-13.385)	<.001	5.332 (3.166-8.982)	<.001
Baseline memory	0.932 (0.904-0.960)	<.001	0.957 (0.939-0.975)	<.001	0.928 (0.903-0.955)	<.001	0.930 (0.911-0.949)	<.001	1.030 (0.856-1.239)	.75	0.849 (0.797-0.904)	<.001
Baseline gait speed, m/s	0.997 (0.200-4.965)	.99	0.196 (0.077-0.503)	<.001	0.183 (0.063-0.536)	.001	0.241 (0.109-0.533)	<.001	0.200 (0.078-0.513)	<.001	0.302 (0.150-0.605)	<.001

Abbreviations: AGES-RS, Age, Gene/Environment Susceptibility-Reykjavik Study; BLSA, Baltimore Longitudinal Study of Aging; Health ABC, Health, Aging and Body Composition Study; HR, hazard ratio; InCHIANTI, Invecchiare in Chianti, Aging in the Chianti Area; MCSA, Mayo Clinic Study of Aging; NA, not applicable; SNAC-K, The Swedish National Study on Aging and Care in Kungsholmen.


^a All models were adjusted for baseline age, sex, and educational level in all studies; additionally adjusted for race/ethnicity in BLSA, Health ABC, and MCSA; and additionally adjusted for site in Health ABC and InCHIANTI.

supports the notion that a 1-time gait speed assessment may be less able than change over time to assess risk of dementia.¹⁰ In all 6 studies, models with change over time significantly improved the assessment of the risk of dementia than models with only information on baseline gait speed and memory. Thus, tracking changes over time may add important information in assessing the risk of developing dementia beyond obtaining a 1-time assessment.

As expected, participants with memory decline had an increased risk of dementia consistently across the 6 cohorts. Our focus on verbal episodic memory, especially immediate recall, rather than global cognition or mental status, allows us to capture early memory decline among Alzheimer disease-related cognitive measures within aging. Focusing on memory, rather than executive function or processing speed, also allows us to better differentiate phenotypic groups because gait speed is associated with executive function within cognitive domains.⁴²

Although participants with gait decline also showed some increased risk of dementia, when accompanied by a parallel decline in objective memory, the risk of developing dementia tended to be the highest among phenotypic groups. Our finding that participants with dual decline are at

Figure. Forest Plots of Hazard Ratios (HRs) for Dementia Risk in Phenotypic Groups



particularly high risk of developing dementia supports the importance of the unique occurring symptom of cognitive and motor deficits outlined in previous research on motoric cognitive risk syndrome and further establishes its clinical relevance. Among older adults living in the community free of cognitive impairment and disability, the dual decline phenotype can be captured early in clinical settings by routinely administering gait speed assessment and a free recall memory test.⁴³ At this stage, this group should be carefully evaluated for potentially reversible risk factors for dementia. However, research focusing on biological and physiological characteristics that explain why individual with dual decline are at such high risk of developing dementia may lead to new opportunities for prevention.

Our findings add weight to the hypothesis that dual decline with aging represents some shared underlying processes associated with declines in both gait and memory that are associated with ultimate overt dementia. Our study may provide a possible explanation for the heterogeneity of reported findings.^{1,3} Perhaps gait speed decline is associated with dementia most particularly when it is at least in part due to incipient central nervous system pathologic characteristics. Our findings that participants with dual decline have the highest risk of dementia capture the critical need for tracking gait and memory and may help isolate potential central nervous system causes of gait decline. An interesting hypothesis is that dual decline may characterize older persons who will eventually progress to dementia through specific pathophysiological mechanisms. Although the nature of these mechanisms is not yet known, we propose that vascular, metabolic, or energetic dysfunction is the likely factor.⁴⁴⁻⁵⁵ This hypothesis should be tested in further studies by examining the particular metabolic, vascular, and neuroimaging features that characterize this specific group.

Our findings do not necessarily address the question as to whether the high risk of dementia associated with dual decline is simply due to the combination of 2 independent factors, gait decline and memory decline, or whether the increased risk represents a shared underlying pathologic condition. Findings varied across the 6 cohorts. Specifically, while the relative risk of dementia associated with dual decline was always higher than the sum of risks due to gait decline and memory decline, the interaction between gait decline and memory decline was significant in 3 studies (BLSA, Health ABC, and SNAC-K). In studies that demonstrated a significant interaction, the period in which gait and memory were assessed was relatively long (mean period, 6-9 years) vs AGES-RS and MCSA (5 years). Although InCHIANTI also had a relatively long period of time assessing gait and memory (9 years), it was somewhat limited by the insensitive measure of memory, based only on the MMSE memory subscore.

Strengths and Limitations

This study has numerous strengths: use of multiple large longitudinal cohort studies, efforts to harmonize measures, careful delineation of individual study approaches to dementia diagnosis, and use of rigorous meta-analytic measures. Accounting for multimorbidity and specific diseases, such as hypertension, cardiovascular disease, and stroke, enriched the analyses, and the findings remained robust. Although a posteriori ascertainment of dementia in 2 studies may have overestimated incident cases, the results remained largely unchanged after excluding these 2 studies.

This study also has some limitations. We acknowledge a lack of information on subtypes of dementia in some studies; thus, we could not evaluate the risk of dementia subtypes. Second, the specific memory measures that we examined in InCHIANTI and MCSA are partly used in dementia diagnostic procedures. However, in InCHIANTI, the MMSE is not the only assessment used to ascertain dementia, and our study used the memory subscore. In MCSA, information from the Rey Verbal Learning Test among all other neuropsychological tests contributed to the determination of a dementia diagnosis.¹⁷ In the other 4 studies, the memory measures that we used in this study are not used in their dementia diagnostic algorithms. Another potential limitation is the possibility of regression to the mean. In some studies, participants with dual decline had higher baseline gait speed and memory performance than usual agers. Participants with dual decline who had higher baseline

gait and memory may have had more room to decline than those with lower baseline performance. However, by adjusting for baseline gait speed and memory, we minimized this possibility.

Conclusions

Our findings have relevant clinical implications and provide important contributions to research on early signs of an underlying dementia process. Older persons with dual decline in memory and gait speed should receive further attention to address issues that may increase dementia risk, including evaluation of cardiovascular and metabolic risk factors. Studying the cardiovascular and metabolic characteristic of this subgroup may provide clues to the specific mechanisms that confer high risk of dementia. Dual decline in memory and gait speed was associated with high risk of developing dementia. These individuals might serve as a valuable target for preventive interventions. Why individual with dual decline are at such a high risk of developing dementia and whether they progress to dementia through distinct mechanisms are not yet known and deserve further investigation.

ARTICLE INFORMATION

Accepted for Publication: December 18, 2018.

Published: February 21, 2020. doi:10.1001/jamanetworkopen.2019.21636

Correction: This article was corrected on April 3, 2020, to fix errors in the Figure and add a sentence to the caption.

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2020 Tian Q et al. *JAMA Network Open*.

Corresponding Author: Qu Tian, PhD, MS, Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, 251 Bayview Blvd, Ste 100, RMO4B316, Baltimore, MD 21224 (qu.tian@nih.gov).

Author Affiliations: Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, Maryland (Tian, Simonsick, Studenski, Ferrucci); Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland (Resnick); Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota (Mielke); Department of Neurology, Mayo Clinic, Rochester, Minnesota (Mielke); Department of Psychiatry, University of California, San Francisco (Yaffe); Department of Neurology, University of California, San Francisco (Yaffe); Department of Epidemiology, University of California, San Francisco (Yaffe); Laboratory of Epidemiology and Population Studies, National Institute on Aging, National Institutes of Health, Baltimore, Maryland (Launer); Faculty of Medicine, University of Iceland, Reykjavik, Iceland (Jonsson); Karolinska Institutet, Aging Research Center, Department of Neurobiology, Care Sciences and Society, Stockholm University, Stockholm, Sweden (Grande, Welmer, Laukka); Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden (Welmer); Karolinska University Hospital, Stockholm, Sweden (Welmer); Stockholm Gerontology Research Center, Stockholm, Sweden (Welmer, Laukka); Geriatric Unit, Azienda Sanitaria di Firenze, Florence, Italy (Bandinelli); Geriatria, Accettazione Geriatrica e Centro di ricerca per l'invecchiamento, IRCCS Istituto Nazionale Ricovero e Cura per Anziani, Ancona, Italy (Cherubini); Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania (Rosano); The Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina (Kritchevsky).

Author Contributions: Drs Tian and Ferrucci had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Tian, Jonsson, Rosano, Kritchevsky, Studenski, Ferrucci.

Acquisition, analysis, or interpretation of data: Tian, Resnick, Mielke, Yaffe, Launer, Grande, Welmer, Laukka, Bandinelli, Cherubini, Simonsick, Studenski, Ferrucci.

Drafting of the manuscript: Tian, Studenski, Ferrucci.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Tian.

Obtained funding: Resnick, Jonsson, Bandinelli.

Administrative, technical, or material support: Resnick, Mielke, Simonsick.

Supervision: Tian, Resnick, Bandinelli, Simonsick, Studenski, Ferrucci.

Conflict of Interest Disclosures: Dr Mielke reported receiving grants from the National Institutes of Health/ National Institute on Aging during the conduct of the study; and receiving grants from Biogen outside the submitted work. Dr Cherubini reported receiving grants from the Italian Ministry of health during the conduct of the study. Dr Studenski reported serving as a consultant on research design for Merck Inc and Biophytis. No other disclosures were reported.

Funding/Support: This research work was supported by the Intramural Research Program of the National Institutes of Health, National Institute on Aging (Drs Tian, Resnick, Launer, Simonsick, Studenski, and Ferrucci). The BLSA was supported by the Intramural Research Program of the National Institutes of Health, National Institute on Aging. The AGES-Reykjavik Study was funded by contract N01-AG-12100 from the National Institutes of Health; by the Intramural Research Program of the National Institute on Aging; and by the Icelandic Heart Association and the Icelandic Parliament. The Health ABC study was supported by National Institute on Aging contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106; National Institute on Aging grant R01-AGO28050; and National Institute of Nursing Research grant R01-NR012459, and was funded in part by the Intramural Research Program of the National Institutes of Health, National Institute on Aging. The MCSA was supported by funding from the National Institutes of Health, National Institute on Aging (U01 AG006786), the Gerald and Henrietta Rauenhorst Foundation, and the Mayo Foundation for Medical Education and Research; and was made possible by the Rochester Epidemiology Project (R01 AG034676). The SNAC-K was supported by the funders of the Swedish National Study on Aging and Care; the Ministry of Health and Social Affairs, Sweden; the participating County Councils and Municipalities; and the Swedish Research Council. The InCHIANTI study was supported by National Institute on Aging contracts 263MD9164 (Dr Ferrucci) and 263 MD 821336, N01-AG-1-1, N01-AG-10211, and N01-AG-5-0002 (Dr Bandinelli), and partially supported by grant n PE 2011 02350413 of the Italian Ministry of Health (Dr Cherubini).

Role of the Funder/Sponsor: The agencies that funded the studies analyzed in this meta-analysis had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Laura Fratiglioni, MD, PhD, Aging Research Center, Karolinska Institutet, provided the SNAC-K data and many useful suggestions that contributed to the manuscript. She was not compensated for her contributions.

REFERENCES

1. Beauchet O, Annweiler C, Callisaya ML, et al. Poor gait performance and prediction of dementia: results from a meta-analysis. *J Am Med Dir Assoc*. 2016;17(6):482-490. doi:10.1016/j.jamda.2015.12.092
2. Valkanova V, Ebmeier KP. What can gait tell us about dementia? review of epidemiological and neuropsychological evidence. *Gait Posture*. 2017;53:215-223. doi:10.1016/j.gaitpost.2017.01.024
3. Peel NM, Alapatt LJ, Jones LV, Hubbard RE. The association between gait speed and cognitive status in community-dwelling older people: a systematic review and meta-analysis. *J Gerontol A Biol Sci Med Sci*. 2019;74(6):943-948. doi:10.1093/gerona/gly140
4. Dumurgier J, Artaud F, Touraine C, et al. Gait speed and decline in gait speed as predictors of incident dementia. *J Gerontol A Biol Sci Med Sci*. 2017;72(5):655-661.
5. Kueper JK, Speechley M, Lingum NR, Montero-Odasso M. Motor function and incident dementia: a systematic review and meta-analysis. *Age Ageing*. 2017;46(5):729-738. doi:10.1093/ageing/afx084
6. Quan M, Xun P, Chen C, et al. Walking pace and the risk of cognitive decline and dementia in elderly populations: a meta-analysis of prospective cohort studies. *J Gerontol A Biol Sci Med Sci*. 2017;72(2):266-270. doi:10.1093/gerona/glw121
7. Rosso AL, Sanders JL, Arnold AM, et al. Multisystem physiologic impairments and changes in gait speed of older adults. *J Gerontol A Biol Sci Med Sci*. 2015;70(3):319-324. doi:10.1093/gerona/glu176
8. Holtzer R, Epstein N, Mahoney JR, Izzetoglu M, Blumen HM. Neuroimaging of mobility in aging: a targeted review. *J Gerontol A Biol Sci Med Sci*. 2014;69(11):1375-1388. doi:10.1093/gerona/glu052
9. Doi T, Makizako H, Tsutsumimoto K, et al. Combined effects of mild cognitive impairment and slow gait on risk of dementia. *Exp Gerontol*. 2018;110:146-150. doi:10.1016/j.exger.2018.06.002
10. Montero-Odasso M, Speechley M, Muir-Hunter SW, et al; Canadian Gait and Cognition Network. Motor and cognitive trajectories before dementia: results from Gait and Brain Study. *J Am Geriatr Soc*. 2018;66(9):1676-1683. doi:10.1111/jgs.15341

11. Doi T, Shimada H, Makizako H, Tsutsumimoto K, Verghese J, Suzuki T. Motoric cognitive risk syndrome: association with incident dementia and disability. *J Alzheimers Dis*. 2017;59(1):77-84. doi:10.3233/JAD-170195
12. Verghese J, Annweiler C, Ayers E, et al. Motoric cognitive risk syndrome: multicountry prevalence and dementia risk. *Neurology*. 2014;83(8):718-726. doi:10.1212/WNL.0000000000000717
13. Verghese J, Wang C, Lipton RB, Holtzer R. Motoric cognitive risk syndrome and the risk of dementia. *J Gerontol A Biol Sci Med Sci*. 2013;68(4):412-418. doi:10.1093/gerona/gls191
14. Chhetri JK, Chan P, Vellas B, Cesari M. Motoric cognitive risk syndrome: predictor of dementia and age-related negative outcomes. *Front Med (Lausanne)*. 2017;4:166. doi:10.3389/fmed.2017.00166
15. Shock NW, Greulich RC, Andres R, et al. Normal human aging: the Baltimore Longitudinal Study of Aging. National Institutes of Health publication No. 84-2450. Washington, DC: US Government Printing Office; 1984.
16. Newman AB, Haggerty CL, Goodpaster B, et al; Health, Aging And Body Composition Research Group. Strength and muscle quality in a well-functioning cohort of older adults: the Health, Aging and Body Composition Study. *J Am Geriatr Soc*. 2003;51(3):323-330. doi:10.1046/j.1532-5415.2003.51105.x
17. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. *Neuroepidemiology*. 2008;30(1):58-69. doi:10.1159/000115751
18. Harris TB, Launer LJ, Eiriksdottir G, et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. *Am J Epidemiol*. 2007;165(9):1076-1087. doi:10.1093/aje/kwk115
19. Ferrucci L, Bandinelli S, Benvenuti E, et al. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. *J Am Geriatr Soc*. 2000;48(12):1618-1625. doi:10.1111/j.1532-5415.2000.tb03873.x
20. Lagergren M, Fratiglioni L, Hallberg IR, et al. A longitudinal study integrating population, care and social services data: the Swedish National study on Aging and Care (SNAC). *Aging Clin Exp Res*. 2004;16(2):158-168. doi:10.1007/BF03324546
21. Cummings SR, Studenski S, Ferrucci L. A diagnosis of disability—giving mobility clinical visibility: a Mobility Working Group recommendation. *JAMA*. 2014;311(20):2061-2062. doi:10.1001/jama.2014.3033
22. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a comprehensive review. *J Am Geriatr Soc*. 1992;40(9):922-935. doi:10.1111/j.1532-5415.1992.tb01992.x
23. Espeland MA, Rapp SR, Shumaker SA, et al; Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. *JAMA*. 2004;291(24):2959-2968. doi:10.1001/jama.291.24.2959
24. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangalos EG. Aging, memory, and mild cognitive impairment. *Int Psychogeriatr*. 1997;9(suppl 1):65-69. doi:10.1017/S1041610297004717
25. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med*. 2004;256(3):183-194. doi:10.1111/j.1365-2796.2004.01388.x
26. Lopez OL, Becker JT, Jagust WJ, et al. Neuropsychological characteristics of mild cognitive impairment subgroups. *J Neurol Neurosurg Psychiatry*. 2006;77(2):159-165. doi:10.1136/jnnp.2004.045567
27. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. *JAMA*. 2011;305(1):50-58. doi:10.1001/jama.2010.1923
28. Best JR, Liu-Ambrose T, Mett AL, et al; Health, Aging and Body Composition Study. Longitudinal associations between walking speed and amount of self-reported time spent walking over a 9-year period in older women and men. *J Gerontol A Biol Sci Med Sci*. 2018;73(9):1265-1271. doi:10.1093/gerona/glx129
29. Mielke MM, Roberts RO, Savica R, et al. Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. *J Gerontol A Biol Sci Med Sci*. 2013;68(8):929-937. doi:10.1093/gerona/gls256
30. Bilgel M, An Y, Lang A, et al. Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample. *Alzheimers Dement*. 2014;10(6):735-742.e4. doi:10.1016/j.jalz.2014.04.520
31. Delis DC, Kramer JH, Kaplan E, Ober BA. *California Verbal Learning Test*. Research ed. New York, NY: Psychological Corporation; 1987.
32. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. *Neurology*. 1974;24(11):1019-1025. doi:10.1212/WNL.24.11.1019
33. Rey A. *Auditory-Verbal Learning Test (AVLT)*. Paris, France: Press Universitaire de France; 1964.
34. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6

35. Laukka EJ, Lövdén M, Herlitz A, et al. Genetic effects on old-age cognitive functioning: a population-based study. *Psychol Aging*. 2013;28(1):262-274. doi:10.1037/a0030829
36. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 3rd ed. Washington, DC: American Psychiatric Association; 1987.
37. Hong CH, Falvey C, Harris TB, et al. Anemia and risk of dementia in older adults: findings from the Health ABC Study. *Neurology*. 2013;81(6):528-533. doi:10.1212/WNL.0b013e31829e701d
38. Cherubini A, Martin A, Andres-Lacueva C, et al. Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. *Neurobiol Aging*. 2005;26(7):987-994. doi:10.1016/j.neurobiolaging.2004.09.002
39. Kwon S, Perera S, Pahor M, et al. What is a meaningful change in physical performance? findings from a clinical trial in older adults (the LIFE-P study). *J Nutr Health Aging*. 2009;13(6):538-544. doi:10.1007/s12603-009-0104-z
40. Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the *Cochrane Handbook for Systematic Reviews of Interventions*. *Cochrane Database Syst Rev*. 2019;10:ED000142. doi:10.1002/14651858.ED000142
41. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008
42. Morris R, Lord S, Bunce J, Burn D, Rochester L. Gait and cognition: mapping the global and discrete relationships in ageing and neurodegenerative disease. *Neurosci Biobehav Rev*. 2016;64:326-345. doi:10.1016/j.neubiorev.2016.02.012
43. Rosano C, Snitz BE. Predicting dementia from decline in gait speed: are we there yet? *J Am Geriatr Soc*. 2018;66(9):1659-1660. doi:10.1111/jgs.15368
44. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. *Arch Neurol*. 2009;66(3):300-305. doi:10.1001/archneurol.2009.27
45. Frisardi V, Solfrizzi V, Seripa D, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. *Ageing Res Rev*. 2010;9(4):399-417. doi:10.1016/j.arr.2010.04.007
46. Gorelick PB, Scuteri A, Black SE, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2011;42(9):2672-2713. doi:10.1161/STR.0b013e3182299496
47. Grande G, Triolo F, Nuara A, Welmer AK, Fratiglioni L, Vetrano DL. Measuring gait speed to better identify prodromal dementia. *Exp Gerontol*. 2019;124:110625. doi:10.1016/j.exger.2019.05.014
48. Hausdorff JM, Buchman AS. What links gait speed and MCI with dementia? a fresh look at the association between motor and cognitive function. *J Gerontol A Biol Sci Med Sci*. 2013;68(4):409-411. doi:10.1093/gerona/glt002
49. Nelson PT, Head E, Schmitt FA, et al. Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. *Acta Neuropathol*. 2011;121(5):571-587. doi:10.1007/s00401-011-0826-y
50. Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. *Alzheimers Dement*. 2015;11(6):710-717. doi:10.1016/j.jalz.2014.10.008
51. Neth BJ, Craft S. Insulin resistance and Alzheimer's disease: bioenergetic linkages. *Front Aging Neurosci*. 2017;9:345. doi:10.3389/fnagi.2017.00345
52. Penninx BW, Nicklas BJ, Newman AB, et al; Health ABC Study. Metabolic syndrome and physical decline in older persons: results from the Health, Aging And Body Composition Study. *J Gerontol A Biol Sci Med Sci*. 2009;64(1):96-102. doi:10.1093/gerona/gln005
53. Yin F, Sancheti H, Patil I, Cadenas E. Energy metabolism and inflammation in brain aging and Alzheimer's disease. *Free Radic Biol Med*. 2016;100:108-122. doi:10.1016/j.freeradbiomed.2016.04.200
54. Cadonic C, Sabbir MG, Albensi BC. Mechanisms of mitochondrial dysfunction in Alzheimer's disease. *Mol Neurobiol*. 2016;53(9):6078-6090. doi:10.1007/s12035-015-9515-5
55. Love S, Miners JS. Cerebrovascular disease in ageing and Alzheimer's disease. *Acta Neuropathol*. 2016;131(5):645-658. doi:10.1007/s00401-015-1522-0

SUPPLEMENT.

eFigure. Kaplan-Meier Survival Curve Between Phenotypic Groups and Dementia Risk

eTable 1. Study Design and Detailed Assessment

eTable 2. Associations of Baseline Gait Speed and Baseline Memory Performance With Phenotypic Groups

eTable 3. Associations of Phenotypic Groups With Dementia Risk After Adjustment for Disease Conditions

eTable 4. Likelihood Ratio Estimates for Model Comparisons

eReferences.